Inhibition of VEGFR-2 reverses type 1 diabetes in nod mice by abrogating insulitis and restoring islet function

Diabetes

Volumn 62, Issue 8, 2013, Pages 2870-2878

  Villalta, S Armando ^a   Lang, Jiena ^a   Kubeck, Samantha ^a   Kabre, Beniwende ^a   Szot, Gregory L ^a   Calderon, Boris ^b   Wasserfall, Clive ^c   Atkinson, Mark A ^c   Brekken, Rolf A ^d   Pullen, Nick ^e   Arch, Robert H ^e   Bluestone, Jeffrey A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d Hamon Center for Therapeutic Oncology Research   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PF 337210; PROTEIN TYROSINE KINASE INHIBITOR; SU 9518; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; SU9518; SUNITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; GLUCOSE TOLERANCE; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; INSULITIS; LYMPHOCYTE MIGRATION; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; HUMAN; INFLAMMATION; METABOLISM; PANCREAS; PATHOLOGY; PATHOPHYSIOLOGY; VASCULARIZATION; DRUG ANTAGONISM; DRUG EFFECT;

ANIMALS; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPERGLYCEMIA; INDOLES; INFLAMMATION; ISLETS OF LANGERHANS; MICE; MICE, INBRED NOD; PANCREAS; PROTEIN KINASE INHIBITORS; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84891716474     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1619     Document Type: Article

References (50)

1. Sreenan S, Pick AJ, Levisetti M, Baldwin AC, Pugh W, Polonsky KS. Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes 1999;48:989-996
2. Alanentalo T, Hörnblad A, Mayans S, et al. Quantification and threedimensional imaging of the insulitis-induced destruction of beta-cells in murine type 1 diabetes. Diabetes 2010;59:1756-1764
3. Sherry NA, Tsai EB, Herold KC. Natural history of beta-cell function in type 1 diabetes. Diabetes 2005;54(Suppl. 2):S32-S39
4. Rossant J, Howard L. Signaling pathways in vascular development. Annu Rev Cell Dev Biol 2002;18:541-573
5. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995;376:66-70
6. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998;95:9349-9354
7. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62-66
8. Huang P, Zhao XS, Fields M, Ransohoff RM, Zhou L. Imatinib attenuates skeletal muscle dystrophy in mdx mice. FASEB J 2009;23:2539-2548
9. Uemura Y, Ohno H, Ohzeki Y, et al. The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis. J Neuroimmunol 2008;195:73-80
10. Paniagua RT, Sharpe O, Ho PP, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006;116:2633-2642
11. Grosios K, Wood J, Esser R, Raychaudhuri A, Dawson J. Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ ZK222584, causes significant anti-Arthritic effects in models of rheumatoid arthritis. Inflamm Res 2004;53:133-142
12. Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 2008;10:R14
13. Ben-Bassat H. Biological activity of tyrosine kinase inhibitors: novel agents for psoriasis therapy. Curr Opin Investig Drugs 2001;2:1539-1545
14. Louvet C, Szot GL, Lang J, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA 2008;105: 18895-18900
15. Hägerkvist R, Sandler S, Mokhtari D, Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-Apoptotic preconditioning. FASEB J 2007;21:618-628
16. Davoodi-Semiromi A, Wasserfall CH, Xia CQ, et al. The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice. PLoS ONE 2012;7:e36079
17. Yoo SA, Kwok SK, Kim WU. Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators Inflamm 2008;2008:129873
18. Chua RA, Arbiser JL. The role of angiogenesis in the pathogenesis of psoriasis. Autoimmunity 2009;42:574-579
19. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009;136:585.e5-595.e5
20. Chiarelli F, Spagnoli A, Basciani F, et al. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabet Med 2000;17:650-656
21. Reinhardt RL, Liang HE, Locksley RM. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol 2009;10:385-393
22. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-337
23. Abdollahi A, Li M, Ping G, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005;201:925-935
24. Marra MT, Khamphavong P, Wisniecki P, Gukasyan HJ, Sueda K. Solution formulation development of a VEGF inhibitor for intravitreal injection. AAPS PharmSciTech 2011;12:362-371
25. Bour-Jordan H, Salomon BL, Thompson HL, Santos R, Abbas AK, Bluestone JA. Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouse. J Immunol 2007;179:1004-1012
26. Chaparro RJ, Konigshofer Y, Beilhack GF, Shizuru JA, McDevitt HO, Chien YH. Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes. Proc Natl Acad Sci USA 2006;103:5-12480
27. Wang ES, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin DJ, Moore MA. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004;104:2893-2902
28. Huggenberger R, Ullmann S, Proulx ST, Pytowski B, Alitalo K, Detmar M. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med 2010;207:2255-2269
29. Chung ES, Chauhan SK, Jin Y, et al. Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3- specific ligands. Am J Pathol 2009;175:1984-1992
30. Sullivan LA, Carbon JG, Roland CL, et al. r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction. PLoS One 2010;5:e12031
31. Ball SG, Shuttleworth CA, Kielty CM. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 2007;177:489-500
32. Calderon B, Carrero JA, Miller MJ, Unanue ER. Cellular and molecular events in the localization of diabetogenic T cells to islets of Langerhans. Proc Natl Acad Sci USA 2011;108:1561-1566
33. Hagberg CE, Mehlem A, Falkevall A, et al. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature 2012;490:426- 430
34. Cross SE, Richards SK, Clark A, et al. Vascular endothelial growth factor as a survival factor for human islets: effect of immunosuppressive drugs. Diabetologia 2007;50:1423-1432
35. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signaling - in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359- 371
36. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2007;2:251-275
37. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/ VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005;109:227-241
38. Yin N, Zhang N, Lal G, et al. Lymphangiogenesis is required for pancreatic islet inflammation and diabetes. PLoS ONE 2011;6:e28023
39. Schonthaler HB, Huggenberger R, Wculek SK, Detmar M, Wagner EF. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci USA 2009;106:21264- 21269
40. Afuwape AO, Feldmann M, Paleolog EM. Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collageninduced arthritis. Gene Ther 2003;10:1950-1960
41. Lee TH, Avraham H, Lee SH, Avraham S. Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells. J Biol Chem 2002;277:10445-10451
42. Goebel S, Huang M, Davis WC, et al. VEGF-A stimulation of leukocyte adhesion to colonic microvascular endothelium: implications for inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2006; 290:G648-G654
43. Boulday G, Haskova Z, Reinders ME, Pal S, Briscoe DM. Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gamma-inducible protein of 10 kDa in vitro and in vivo. J Immunol 2006;176:3098-3107
44. Akirav EM, Baquero MT, Opare-Addo LW, et al. Glucose and inflammation control islet vascular density and beta-cell function in NOD mice: control of islet vasculature and vascular endothelial growth factor by glucose. Diabetes 2011;60:876-883
45. Agudo J, Ayuso E, Jimenez V, et al. Vascular endothelial growth factormediated islet hypervascularization and inflammation contribute to progressive reduction of β-cell mass. Diabetes 2012;61:2851-2861
46. Davoodi-Semiromi A, Hassanzadeh A, Wasserfall CH, Droney A, Atkinson M. Tyrphostin AG490 agent modestly but significantly prevents onset of type 1 in NOD mouse; implication of immunologic and metabolic effects of a Jak-Stat pathway inhibitor. J Clin Immunol 2012;32:1038-1047
47. Hägerkvist R, Makeeva N, Elliman S, Welsh N. Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro. Cell Biol Int 2006;30:1013-1017
48. Gu JJ, Zhang N, He YW, Koleske AJ, Pendergast AM. Defective T cell development and function in the absence of Abelson kinases. J Immunol 2007;179:7334-7343
49. Sherry NA, Chen W, Kushner JA, et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 2007;148:5136-5144
50. Ablamunits V, Henegariu O, Hansen JB, et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 2012;61:145-154